Jill Feldman: Dosing studies are critical!

Jill Feldman, Co-Founder of EGFR Resisters, shared a post on X:

“Dosing studies are critical!
OS and QOL both matter and pts/fam are the ONLY ones who can choose what matters most to THEM Amgen Oncology (and many others) please consider alternate doses while doing further studies
PhRMA, please push MED (minimal effective), NOT MTD.”

Read further.
Source: Jill Feldman/X